**DIAGNOSTIC CRITERIA/ EVALUATION**

<table>
<thead>
<tr>
<th>Mild Cognitive Impairment (MCI)</th>
<th>Dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td></td>
</tr>
<tr>
<td>Cognitive decline greater than expected for age and education level without significantly interfering with activities of daily life.</td>
<td>Cognitive impairment with:</td>
</tr>
<tr>
<td>Evidence of memory impairment</td>
<td>significant decline from previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, social cognition, perceptual motor)</td>
</tr>
<tr>
<td>Preservation of general cognitive and functional abilities</td>
<td>interference with independence in daily activities</td>
</tr>
<tr>
<td>Absence of diagnosed dementia</td>
<td>Not occurring exclusively with delirium</td>
</tr>
<tr>
<td></td>
<td>Not better explained by another disorder</td>
</tr>
<tr>
<td></td>
<td>Neurobehavioral abnormalities</td>
</tr>
<tr>
<td><strong>History</strong></td>
<td></td>
</tr>
<tr>
<td>MCI and Dementia patients may have similar historical findings which contribute to the ultimate diagnosis:</td>
<td></td>
</tr>
<tr>
<td>- Poor adherence to rules and routines</td>
<td></td>
</tr>
<tr>
<td>- Personal hygiene problems</td>
<td></td>
</tr>
<tr>
<td>- Impaired comprehension</td>
<td></td>
</tr>
<tr>
<td>- History of head injury, substance abuse, or other medical contributors</td>
<td></td>
</tr>
<tr>
<td><strong>Differential Diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>Medication effects</td>
<td>Medication effects</td>
</tr>
<tr>
<td>Depression/other psychiatric disorders</td>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Brain lesion</td>
<td>B 12 deficiency</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>Tertiary syphilis (extremely rare in US)</td>
</tr>
<tr>
<td>B 12 deficiency</td>
<td>Brain lesion</td>
</tr>
<tr>
<td></td>
<td>Depression/other psychiatric disorder</td>
</tr>
<tr>
<td><strong>Risk Factors</strong></td>
<td></td>
</tr>
<tr>
<td>&gt; 50% of MCI patients progress to dementia within 5 years.</td>
<td>Age: Alzheimer’s Disease (AD) incidence 1% age 70, increasing to about 50% in those &gt; 85 years</td>
</tr>
<tr>
<td>Consider screening of MCI patients</td>
<td>Family History: 10-30% AD risk in first degree relatives of AD patients</td>
</tr>
<tr>
<td>May consider screening for MCI/dementia in patients &gt; 65 years</td>
<td>Vascular Disease Risk Factors</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td></td>
</tr>
<tr>
<td>Anxiety over memory impairment</td>
<td>Memory loss, neurobehavioral abnormalities: aggressive or inappropriate behavior, poor self control, anxiety, agitation, denial, confabulation</td>
</tr>
<tr>
<td>Difficulty with decision-making</td>
<td>AD is the most common form of dementia. Other types: Vascular, Lewy Body Dementia, Parkinson’s Disease Dementia, etc. (see page 4)</td>
</tr>
<tr>
<td>Able to perform most tasks but these may be more difficult and require more time</td>
<td>Symptoms often first noted by others: cellmate, custody staff, others</td>
</tr>
<tr>
<td>May be ‘amnestic’ when memory domain affected or ‘nonamnestic’ when impairment is in a nonmemory domain</td>
<td>Universal screening not recommended</td>
</tr>
<tr>
<td><strong>Evaluation</strong></td>
<td></td>
</tr>
<tr>
<td>TSH, vitamin B12. Other screening labs show little evidence of benefit (CBC, CMP, HIV serology, lipids, ESR, RPR, drug screen)</td>
<td>TSH, B12. Other screening labs show little evidence of benefit (CBC, CMP, HIV serology, lipids, ESR, RPR, drug screen)</td>
</tr>
<tr>
<td>Cognitive assessment –Mini-Cog, MOCA, Clock Drawing Test,</td>
<td>Imaging: Consider MRI w/o contrast (1st choice). [MRI with contrast if vascular or mixed dementia suspected]</td>
</tr>
<tr>
<td>Mental Health evaluation to identify:</td>
<td>Consider CT w/o contrast to exclude structural causes of dementia (may be used to assess hippocampal atrophy to support AD diagnosis)</td>
</tr>
<tr>
<td>- Pseudodementia (depression)</td>
<td>Cognitive assessment with Mini-Cog, MOCA, Clock Drawing Test,</td>
</tr>
<tr>
<td>- Underlying mental health diagnosis impairing cognition</td>
<td>Adaptive needs evaluation by DDP clinician for functional capacity or accommodation needs</td>
</tr>
<tr>
<td>- Cognitive impairment due to substance abuse</td>
<td>Mental Health evaluation to identify:</td>
</tr>
<tr>
<td>- Suicide risk</td>
<td>- Pseudodementia (depression)</td>
</tr>
<tr>
<td></td>
<td>- Underlying mental health diagnosis impairing cognition</td>
</tr>
<tr>
<td></td>
<td>- Cognitive impairment due to substance abuse</td>
</tr>
<tr>
<td></td>
<td>- Suicide risk</td>
</tr>
</tbody>
</table>

**Alerts**

- Victimized patients
- Increase in rules violation behaviors
- Worsening personal hygiene
- Anxiety and agitation, especially at night
- Complete Advance Directive-Durable Power of Attorney for Health Care (DPAHC) early in course of disease
- Prison environment may mask symptoms
TREATMENT OPTIONS:

**BEHAVIORAL INTERVENTIONS**
- Exercise
- Social interaction
- Skills to promote good sleep hygiene
- Engagement in simple tasks
- Cognitive stimulation therapy (e.g. physical games, sound and word association)

**ENVIRONMENTAL / SOCIAL**
- Safe Housing will be provided for patients with adaptive needs.
- Assistance with ADLs and for other activities as needed.
- Ensure timely completion of Advance Directive-DPAHC/POLST
  - Assess decision-making capacity (consult with Care Team, Medical Management, Mental Health, and/or institution or headquarters Ethics Committee).
  - Custody Counseling Staff may be of assistance in locating family or friends who may serve as surrogate decision-maker

**PHARMACOLOGIC MANAGEMENT**
- Review all prescribed medications to determine potential for medication-related cognitive impairment
- Dementia specific medication (donepezil, galantamine, rivastigmine, memantine) may delay progression of disease by several months, but providers must be aware of marginal benefit and potential adverse effects of these medications. Donepezil is preferred formulary agent (page 10).
- For behavior disturbances in dementia:
  - Attempt to minimize anticholinergic burden if clinically appropriate
  - Dementia specific agents (e.g., cholinesterase inhibitors, glutamate antagonists), SSRIs, oxcarbazepine, buspirone, or valproic acid may be effective for mild behavior disturbances associated with dementia
  - Antipsychotics may be indicated to manage more severe aggressive behavior or psychosis but may exacerbate cognitive deficit. Increased stroke risk is reported with any antipsychotic in the elderly. Used only with careful consideration of the risks and if no reasonable alternative behavioral management options are available.
- Cardiovascular risk reduction as indicated (low dose aspirin, lipid lowering agents, antihypertensives, etc.)

**MONITORING:**
- Assess status of cognitive function (MOCA or Mini-Cog or other tool)
- Medication monitoring
  - Ask patient and/or caregiver about medication effectiveness and side effects
  - Reassess 6–8 weeks after initiating any dementia-specific medications, and at least every 6 months
  - Reassess for continued need of every medication(s) and discontinue any medication without clear benefit to patient
- Evaluate mood and behavior with input from caregivers and observers.
- Reassess appropriateness of housing with consideration of behavior problems and safety concerns.
- Assess for sleep dysfunction.
- Follow-up frequency will vary. Well controlled patients may be seen by PCP at 90-180 day intervals.

### MEDICATIONS WHICH MAY IMPAIR COGNITION*

<table>
<thead>
<tr>
<th>Anticholinergics</th>
<th>Ipratropium, tiotropium, benztropine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle relaxants</td>
<td>Methocarbamol, cyclobenzaprine, carisoprolod</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Diphenhydramine, chlorpheniramine, promethazine, hydroxyzine</td>
</tr>
<tr>
<td>Antimuscarinics</td>
<td>Oxybutynin, tolterodine, darifenacin, trospium, fesoterodine (Used for urinary urge incontinence and overactive bladder)</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Tricyclic antidepressants, mirtazapine, trazodone, bupropion, SSRIs, lithium, MAO inhibitors</td>
</tr>
<tr>
<td>Antiepileptic Drugs</td>
<td>Valproate, phenytoin, carbamazepine, gabapentin, levetiracetam, topiramate, lamotrigine, pregabalin, clonazepam</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>Chlorpromazine, haloperidol, prochlorperazine, fluphenazine, risperidone, quetiapine, aripiprazole, olanzapine, ziprasidone</td>
</tr>
<tr>
<td>Sedatives</td>
<td>Benzodiazepines, buspirone, barbiturates</td>
</tr>
<tr>
<td>Opiates</td>
<td>Codeine (cough syrup), morphine, oxycodone, hydrocodone, methadone, etc.</td>
</tr>
<tr>
<td>Antiparkinson Meds</td>
<td>L-dopa, bromocriptine, amantadine</td>
</tr>
<tr>
<td>Other</td>
<td>Hyoscyamine, cimetidine, clonidine, azapirone</td>
</tr>
</tbody>
</table>

*Not a complete list.
See prescribing information for prescribed medications in individual patients to assess risk of cognitive impairment from medications.
**SUMMARY**

**DECISION SUPPORT**

**PATIENT EDUCATION/ SELF MANAGEMENT**

---

**EVALUATION AND MANAGEMENT ALGORITHM - MCI*/Dementia**

1. Mental Health Evaluation and DDP Assessment
   a. diagnose mental health disorder impairing cognition
   b. identify any other mental health disorder
   c. determine need to admit to the Mental Health Services Delivery System
   d. determine need for adaptive support

2. Indication for inclusion in Mental Health Services Delivery System (MHSDS)?
   - Yes: Enroll in Mental Health Services Delivery System. Patients with evidence of mental health disorder and MCI/Dementia will be co-managed by mental health and medical providers.
   - No

3. Indication for adaptive support?
   - Yes: **DDP Placement**
   - No

4. Support for MCI or Dementia Diagnosis?
   - Yes
     - PCP confirms diagnosis of MCI or Dementia
     - Mental Health informed of Dementia Dx. Regular Mental Health follow-up to assess adaptive support needs.
     - Continue Primary Care Management
     - PCP to attempt completion of Advance Directive for Healthcare (CDCR-7421) - DPAHC
     - Consider notice to custody regarding other Durable Powers of Attorney (e.g. property)

   - No

**Notes:**
- **MCI** = Mild Cognitive Impairment
- **DDP** = Developmental Disabilities Program
- Purpose of Developmental Disabilities Program (DDP) Evaluation
  - Assesses individual’s needs for adaptive support
  - Evaluates victimization issues

---

December 2014

CCHCS Care Guide: Cognitive Impairment/Dementia
<table>
<thead>
<tr>
<th>TYPE</th>
<th>CHARACTERISTICS</th>
</tr>
</thead>
</table>
| Alzheimer's Disease (AD)                          | - About 50% of dementia cases  
- Gradual onset with continuing decline  
- Difficulty remembering names, recent events, apathy & depression  
- Progressive decline in cognition and functional ability which is not caused by identifiable medical, psychiatric, or neurological condition  
- Late: Behavior problems, impaired judgment, orientation, confusion, difficulty walking, speaking, swallowing.                                                                                                                                                           |
| Vascular (multi-infarct) Dementia                 | - About 25% of dementia cases.  
- Symptoms similar to those of AD but focal neurological signs or evidence of a cerebrovascular process severe enough to cause dementia are common.  
- History of multiple TIAs or two or more ischemic strokes.  
- In general, patients with vascular dementia have a more ‘stepwise’ decline, while patients with Alzheimer’s have a more gradual decline in cognitive function.  
- Patients have changes on brain imaging characterized by cortical infarcts, multiple lacunae and extensive white matter changes.  
- Depression and atrophy are common.                                                                                                                                                                                                                                                                 |
| Dementia with Lewy Bodies (DLB)                   | - 15% of dementia cases  
- History of fluctuating cognitive performance  
- Gait and balance disorders, visuospatial function and attention affected more than memory  
- Recurrent visual hallucinations and delusions (unrelated to dopaminergic therapy)  
- Fluctuating confusion with variation in cognitive function over minutes, hours, days, or weeks  
- Motor symptoms of Parkinsonism.  
- Associated features: falls, disturbances of consciousness, autonomic dysfunction, REM sleep behavior disorder.                                                                                                                                                                                                 |
| Parkinson’s Disease Dementia (PDD)               | - 5% of dementia cases  
- Parkinson’s-associated dementia is characterized by onset of Parkinson’s disease symptoms before the onset of dementia. Usually develops in later stages of Parkinson’s Disease  
- Antiparkinson’s agents (notably anticholinergics, L-Dopa, amantadine) can exacerbate symptoms                                                                                                                                                                                                 |
| Other                                             | - Evidence from history, physical exam, or laboratory findings of a specific medical condition causing cognitive deficits (Frontotemporal Dementia, Parkinson’s disease, traumatic brain injury, substance/medication abuse, HIV infection, Huntington's Chorea, Pick's disease, Creutzfeldt-Jakob disease), or another medical condition (late syphilis, Lyme disease, tuberculosis, SLE, Sjogren's syndrome, depression, brain tumor, normal pressure hydrocephalus).  
- Frontotemporal Dementia onset often at 55 to 60 years (younger than AD) and usually presents with language disturbance and/or behavioral difficulties such as disinhibition, difficulty with language and speech and abnormal social behavior  
- Pick's disease is a subtype of frontotemporal dementia.  
- Mixed Dementia very common in elderly (AD, vascular, and Lewy Bodies). |
### Instructions for Administration of the Mini-Cog™

<table>
<thead>
<tr>
<th>Administration</th>
<th>Special Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Three Word Recall</td>
<td>The following word lists have been used in one or more clinical studies: 1-3</td>
</tr>
</tbody>
</table>
| Get patient’s attention. Say: “I am going to say three words that I want you to remember. The words are (select from word list).” “Please say them for me now.” If patient is unable to repeat after 3 tries, then go to clock drawing test. | - Version 1  - Banana  - Village  - Captain  - Version 5  
- Version 2  - Sunrise  - Kitchen  - Garden  
- Version 4  - Chair  - Baby  - Picture  
- Version 6  - Daughter  - River  - Leader  
- Version 3  - Heaven  - Nation  - Season  
- Mountain  - Finger  - Table |
| 2. Clock Drawing Test (CDT) | - A clock should not be visible to the patient during this task. Use either a blank piece of paper and have patient draw circle OR provide a preprinted circle – administration would then be to ask the patient to put in all the numbers like the face of a clock. Repeat instructions as needed. This is not a memory test. Move to next step if clock is not complete within 3 minutes. Inability or refusal to draw a clock is scored abnormal (0 points). |
| Say in order: “Please draw a clock. Start by drawing a large circle.” (when done, say) “Put all the numbers in the circle.” (when done, say) “Now set the hands to show 11:10 (10 past 11) OR 8:20 OR 1:45.” | Ask the patient to recall the three words you stated in Step 1. |
| 3. Say: “What were the three words I asked you to remember?” | |

### Scoring

| Word recall | (0-3 points) | 1 point for each word spontaneously recalled without cueing. |
| Clock draw | (0 or 2 points) | - Normal clock = 2 points. A normal clock has all numbers placed in the correct sequence and approximately correct position (e.g., with 12, 3, 6, and 9 in anchor positions) with no missing or duplicate numbers. Hands are pointing to the 11 and 2 (11:10) or the 8 and 4 (8:20) or 1 and 9 (1:45). (Length of hands less important). Abnormal clock = 0 points. |

Total = (0-5 points)  
Total score = word recall score + clock score  
Negative screen for cognitive impairment: Mini-Cog™ 4-5 score  
Positive screen for cognitive impairment: Mini-Cog™ 0-3 score

### References/Copyright Information


**Clock Drawing Test:** Useful to screen for mild cognitive impairment (very short but not reliable or accurate enough for routine clinical use alone)  
**Mini-Cog (includes Clock Drawing Test)**— useful to screen for dementia, compares well with longer screening tests in helping detect dementia (76-99% sensitivity, 89-93% specificity).
Montreal Cognitive Assessment: Developed as a rapid screening instrument for detection of mild cognitive impairment.

MoCA® may be used, reproduced, and distributed without permission by Hospitals/Clinics.

Copyright © Dr Z. Nasreddine 2003 to 2014 - The Montreal Cognitive Assessment - MoCA® - All rights reserved.

http://www.mocatest.org/permission.asp
## Medications Used to Treat Dementia:

Literature suggests that dementia specific medications are of limited benefit and they are associated with significant toxicity. It is very important for prescribers to consider benefits and risks before starting one of these agents and to regularly assess the patient and to discontinue the medication when there is no evidence of benefit or with disease progression.

### Cholinesterase Inhibitors: Donepezil, galantamine, and rivastigmine appear to have similar efficacy, donepezil appears to have fewer side effects

<table>
<thead>
<tr>
<th>Medication</th>
<th>Usage</th>
<th>Side Effects*</th>
<th>Contraindications */ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>donepezil</strong></td>
<td><strong>Indication:</strong> mild to moderate Alzheimer’s Disease</td>
<td><strong>Serious Reactions:</strong> AV Block, syncope, seizures</td>
<td><strong>Caution in bradycardia or conduction abnormalities (sick sinus syndrome, left bundle branch block)</strong></td>
</tr>
<tr>
<td><strong>(Aricept&lt;sup&gt;®&lt;/sup&gt;)</strong></td>
<td><strong>Initial dose:</strong> 5 mg/day at bedtime. May increase to 10 mg/day after 4-6 weeks. Moderate to severe AD: Initial dose: 5 mg/day. May increase to 10 mg/day after 4-6 weeks. May consider increase to 23 mg/day after 3 months.</td>
<td><strong>Common Reactions:</strong> Diarrhea, nausea, vomiting, dyspepsia, weight loss, insomnia, fatigue, dizziness, headache</td>
<td><strong>Avoid in patients with uncontrolled asthma/COPD or active peptic ulcer disease (PUD)</strong></td>
</tr>
<tr>
<td><strong>Tabs:</strong> 5 mg, 10 mg, 23 mg</td>
<td><strong>Oral dispersible tablet (ODT):</strong> 5 mg, 10 mg</td>
<td><strong>Initial Dose:</strong> IR tablet: 4 mg orally twice daily with food. ER tablet: 8 mg once daily. After 4 weeks at initial dose, may increase dose at 4 week intervals to 16-24 mg per day in 2 divided doses (IR) or once daily (ER). If therapy interrupted three or more days, restart at lowest dose.</td>
<td><strong>Serious Reactions:</strong> AV Block, bradycardia, syncope, seizures, urinary obstruction, Nausea, anorexia, vomiting, and diarrhea, weight loss, dizziness, headache, insomnia</td>
</tr>
<tr>
<td><strong>Razadyne&lt;sup&gt;®&lt;/sup&gt;</strong></td>
<td><strong>Capsules:</strong> 1.5 mg, 3 mg, 4.5 mg, 6 mg</td>
<td><strong>Initial Dose:</strong> 1.5 mg orally twice daily with food. May increase by 3 mg/day every two weeks&lt;sup&gt;6&lt;/sup&gt; to maximum 6 mg twice daily. Usual dose 9-12 mg divided twice daily. If therapy interrupted three or more days, restart at lowest dose.</td>
<td><strong>Serious Reactions:</strong> Stevens-Johnson Syndrome, bradycardia, hypotension, Adams-Stokes syndrome, CNS depression may impair alertness,</td>
</tr>
<tr>
<td><strong>Capsules:</strong> 4.6 mg/24 hour, 9.5 mg/24 hour, 13.3 mg/24 hr</td>
<td><strong>Transdermal patches:</strong> 4.6 mg/24 hour, 9.5 mg/24 hour, 13.3 mg/24 hr</td>
<td><strong>Initial Dose:</strong> IR tablet: 5 mg orally daily. Increase at weekly intervals by 5 mg/day to max dose 20 mg/day. Give doses &gt; 5 mg/day in 2 divided doses. ER capsule: 7 mg once daily up to target of 28 mg once daily. Wait at least 1 week between dose changes.</td>
<td><strong>Common Reactions:</strong> Syncope, dizziness, falling, headache, agitation, nausea, vomiting (sometimes severe), diarrhea, weight loss, abdominal pain, tremor, Insomnia, somnolence</td>
</tr>
<tr>
<td><strong>Namenda&lt;sup&gt;®&lt;/sup&gt;</strong></td>
<td><strong>IR tablets:</strong> 5 mg, 10 mg, ER capsules: 7 mg, 14 mg, 21 mg, 28 mg</td>
<td><strong>Indication:</strong></td>
<td><strong>Serious Reactions:</strong> Stevens-Johnson Syndrome,</td>
</tr>
<tr>
<td><strong>NMDA (N-methyl-D-aspartate) Glutamate Antagonist</strong></td>
<td><strong>Initial dose:</strong> IR tablet: 5 mg orally daily. Increase at weekly intervals by 5 mg/day to max dose 20 mg/day. Give doses &gt; 5 mg/day in 2 divided doses. ER capsule: 7 mg once daily up to target of 28 mg once daily. Wait at least 1 week between dose changes.</td>
<td><strong>Common Reactions:</strong> Dizziness, headache, confusion, constipation, diarrhea HTN, fatigue, syncope</td>
<td><strong>Avoid in patients with uncontrolled asthma/COPD or active peptic ulcer disease (PUD)</strong></td>
</tr>
<tr>
<td><strong>memantine</strong></td>
<td><strong>Indication:</strong></td>
<td></td>
<td><strong>Caution in mild or moderate renal or hepatic impairment, avoid with severe renal or hepatic disease</strong></td>
</tr>
</tbody>
</table>

* For complete lists of side effects, drug interactions, and contraindications consult prescribing information.

**Bold = Formulary**
What is dementia? Dementia is a disease that destroys brain cells and brain function. It can affect your memory and the way you think. There are different kinds of dementia and every case is different. Your doctor will help keep track of your symptoms and your needs.

What symptoms does dementia cause? Symptoms of dementia often start off very mild and get worse slowly. Symptoms can include:

- Forgetting all sorts of things
- Confusion
- Trouble with language (for example, not being able to find the right words for things)
- Trouble concentrating and reasoning
- Problems with tasks such as paying bills or balancing a checkbook
- Getting lost in familiar places

As dementia gets worse, it can cause:

- Anger or aggression
- A person to see things that aren’t there or believe things that aren’t true
- Impair ability to eat, bathe, dress, or do other everyday tasks
- Loss of bladder and bowel control

How is dementia treated? That depends on what your needs are and the type of dementia you have.

- Medical staff will watch your symptoms and work with you to find solutions to the problems that might come up.
- You will be taught new skills to help you remember things and organize your day better.
- If you have Alzheimer’s Disease, there are medicines that might help.
- If you have dementia related to your blood circulation, your doctor will work on keeping your blood pressure and cholesterol as close to normal as possible to reduce further injury to your brain.
- If you get anxious or depressed your doctor may prescribe medication.

Can dementia be prevented? — There are no proven ways to prevent dementia. But here are some things that seem to help keep the brain healthy:

- Physical activity
- Social interaction
- Keeping the brain busy, for example by reading or doing puzzles
WHAT YOU SHOULD KNOW

Patients with dementia often have so much trouble with thinking and memory that they are not able to tell the doctor their wishes for medical treatment. This is especially true when it comes to wishes about end of life treatment including being on machines or having a feeding tube. Writing down your wishes now will help be sure they are followed later.

What is advance care planning?
- Thinking and planning ahead about what kind of medical care you want as you get sicker.
- The kind of medical treatment you want usually depends on what is important to you.
- Talking about your wishes with loved ones and your doctors and nurses and writing them down will help make sure that your wishes are followed.

What is an Advance Directive?
- Advance Directives are papers used to write down your wishes for end of life care.
- They allow you to say what you want so that family, friends, doctors, and nurses will know for sure what you want if you can no longer speak for yourself.
- An Advance Directive allows you to choose someone to make medical decisions for you if you can no longer make them.
- In CDCR we use CDCR Form 7421 Advance Directive for Health Care.

Listed below are some of the things to consider regarding your end of life wishes. You may wish to circle the items that are most important to you to discuss with your provider when you complete your Advance Directive.
- Physical comfort
- Relief of pain and distress
- To die naturally
- To live as long as possible no matter what
- To be able to care for my physical needs
- To be able to recognize family & friends
- To be able to make my own decisions
- To receive palliative (comfort) care & hospice
- Would you want to have CPR done?
- Would you want a feeding tube?
- Would you want to be kept alive by machines (ventilator) in the following cases?:
  - If my brain's thinking functions were destroyed?
  - If I were near death with a terminal illness?
- Is there a person you want to help attend to your spiritual needs as death nears?
- Is there someone you wish to have make medical decisions for you (called a health care surrogate or agent) when/if you are no longer able to speak for yourself?
- If you are very sick and near the end of your life is there a family member/friend you would like to called?
- Is there someone different to call after your death?

Q: What if I change my mind?
- You may complete a new Advance Directive (CDCR Form 7421) at any time as your wishes change. You may complete an Advance Directive even when you are young and perfectly healthy.

TALK TO YOUR DOCTOR OR ANY MEMBER OF YOUR HEALTH CARE TEAM TO COMPLETE OR UPDATE YOUR ADVANCE DIRECTIVE.